<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662489</url>
  </required_header>
  <id_info>
    <org_study_id>ARTIST</org_study_id>
    <nct_id>NCT04662489</nct_id>
  </id_info>
  <brief_title>Radial Ablation for the Control of Persistent Atrial Fibrillation</brief_title>
  <acronym>ARTIST</acronym>
  <official_title>Radial Ablation for the Control of Persistent Atrial Fibrillation (Ablación Radial Para conTrol de la fibrilación Auricular persISTtente)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Innovacion en Biomedicina (FIBMED)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Innovacion en Biomedicina (FIBMED)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol aims to evaluate the efficacy of the radial ablation technique of the&#xD;
      maintenance mechanisms in persistent atrial fibrillation compared to the isolation of the&#xD;
      pulmonary veins evaluating the atrial fibrillation burden during one year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is the most common arrhythmia in clinical practice, and its treatment&#xD;
      still remains suboptimal. Electrical isolation of the pulmonary veins with radiofrequency&#xD;
      ablation or cryoablation is the standard therapy when antiarrhythmic drugs or electrical&#xD;
      cardioversion is not successful. However, recurrence after catheter ablation worsens in&#xD;
      persistent and permanent atrial fibrillation patients. Recently, rotational activity&#xD;
      electrogram patterns of self-sustained electrical activity found in the atria have been&#xD;
      proposed as the responsible mechanism for the maintenance of atrial fibrillation. The&#xD;
      investigators devised a controlled, multicentric, prospective, not blinded, and a randomized&#xD;
      clinical trial with the aim of comparing pulmonary vein catheter ablation versus radial&#xD;
      ablation of sites exhibiting rotational activity in patients with persistent atrial&#xD;
      fibrillation. Radial ablation consists of the ablation of the rotational activity sites and&#xD;
      an additional ablation line connecting the rotation site with the circumferential ablation&#xD;
      line of the pulmonary veins.&#xD;
&#xD;
      Besides, substudies ARTIST-Gender and ARTIST-HF will be performed. ARTIST-Gender will compare&#xD;
      the same outcomes and analysis of the patient cohort but according to the gender of the&#xD;
      patient, and ARTIST-HF will sub-divide the analysis with respect to heart failure present in&#xD;
      the enrolled patients' cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control and treatment arms. Control group refers to pulmonary vein isolation ablation. Treatment group refers to pulmonary vein isolation plus radial ablation of rotational activity sites.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation burden (1 year)</measure>
    <time_frame>Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Atrial fibrillation burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial fibrillation episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial fibrillation burden (1 year)</measure>
    <time_frame>Analysis by gender. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-Gender. Atrial fibrillation burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial fibrillation episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial fibrillation burden (1 year)</measure>
    <time_frame>Analysis by heart failure presence. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-HF. Atrial fibrillation burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial fibrillation episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial flutter burden (1 year)</measure>
    <time_frame>Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Atrial flutter burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial flutter episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial flutter burden (1 year)</measure>
    <time_frame>Analysis by gender. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-Gender. Atrial flutter burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial flutter episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial flutter burden (1 year)</measure>
    <time_frame>Analysis by heart failure presence. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-HF. Atrial flutter burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial flutter episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial tachycardia burden (1 year)</measure>
    <time_frame>Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Atrial tachycardia burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial tachycardia episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial tachycardia burden (1 year)</measure>
    <time_frame>Analysis by gender. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-Gender. Atrial tachycardia burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial tachycardia episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial tachycardia burden (1 year)</measure>
    <time_frame>Analysis by heart failure presence. Patients will be followed up during one year, regardless of reaching or not the primary endpoint.</time_frame>
    <description>Substudy ARTIST-HF. Atrial tachycardia burden. Holter monitoring at 4, 8 and 12 months. Time to first atrial tachycardia episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe complication of the ablation procedure</measure>
    <time_frame>2 years</time_frame>
    <description>Occurrence of severe complications of the ablation procedure Will be identified through review of patient clinical reports. One week post-procedural complications included.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall clinical procedure, radiofrequency and fluoroscopy durations</measure>
    <time_frame>2 years</time_frame>
    <description>Total time registered during the clinical procedure.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accute procedural success rate</measure>
    <time_frame>2 years</time_frame>
    <description>Accute procedural success as the percentage of episodes that revert to sinus flutter or sinus rhythm during the ablation procedure.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hospitalization for cardiovascular cause</measure>
    <time_frame>1 year</time_frame>
    <description>Unforeseen hospitalization for cardiovascular cause requiring overnight hospital stay during the 12 month follow-up.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident unforeseen hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Unforeseen hospitalization due to cerebrovascular accident (CVA) requiring overnight hospital stay during the 12 month follow-up.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure unforeseen hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Unforeseen hospitalization due to new diagnosis for heart failure requiring overnight hospital stay during the 12 month follow-up.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional class worsening unforeseen hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Unforeseen hospitalization due to functional class worsening due to heart failure requiring overnight hospital stay during the 12 month follow-up.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final functional class at the end of the study</measure>
    <time_frame>2 years</time_frame>
    <description>Final functional class at the end of the study. New York Heart Association (NYHA) classification.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and cardiac mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Total and cardiac mortality&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with the The Short Form (36) Health Survey</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life is measured with the The Short Form (36) Health Survey at pre-specified study follow-up visits (4, 8, 12 months).&#xD;
The short-form (36) health survey consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.&#xD;
Extended analysis by gender and heart failure presence in substudies ARTIST-Gender and ARTIST-HF.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control arm. Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation with ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm. Radial ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein isolation plus radial ablation of rotational activity sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein electrical isolation</intervention_name>
    <description>Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy</description>
    <arm_group_label>Control arm. Pulmonary vein isolation</arm_group_label>
    <other_name>Pulmonary veins ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radial ablation</intervention_name>
    <description>Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.</description>
    <arm_group_label>Treatment arm. Radial ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years.&#xD;
&#xD;
          -  Non-valvular symptomatic persistent atrial fibrillation.&#xD;
&#xD;
          -  Patient willingness to participate in the study providing signed written informed&#xD;
             consent.&#xD;
&#xD;
          -  Failure or drug intolerance or refusal to continue with chronic antiarrhythmic&#xD;
             treatment.&#xD;
&#xD;
          -  Left ventricular ejection fraction LVEF) ≥ 25 % in the last echocardiogram prior to&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left atrial diameter &gt; 5.5 cm in the last echocardiogram.&#xD;
&#xD;
          -  Contraindication of chronic anticoagulation or heparin.&#xD;
&#xD;
          -  Previous atrial fibrillation ablation procedure.&#xD;
&#xD;
          -  Acute coronary syndrome, cardiac surgery or acute cerebrovascular accident in two&#xD;
             months prior to enrollement.&#xD;
&#xD;
          -  Previous diagnosis for hyperthyroidism or hypothyroidism.&#xD;
&#xD;
          -  Mental or physical illness that disables the patient to participate in the study.&#xD;
&#xD;
          -  Scheduled cardiac percutaneous or surgical intervention.&#xD;
&#xD;
          -  Non-controlled hypertension &gt; 160/100.&#xD;
&#xD;
          -  Terminal renal insufficiency or dialysis.&#xD;
&#xD;
          -  Functional class IV of the New York Heart Association (NYHA).&#xD;
&#xD;
          -  Moderate valvular disease or previous mitral prosthesis.&#xD;
&#xD;
          -  Previous hypertrophic heart disease.&#xD;
&#xD;
          -  Life expectancy less than 12 months.&#xD;
&#xD;
          -  Inclusion on the transplant list.&#xD;
&#xD;
          -  Participation in another study so as not to interfere with the results.&#xD;
&#xD;
          -  Previous atrioventricular block.&#xD;
&#xD;
          -  Pericardial effusion.&#xD;
&#xD;
          -  Pregnancy or childbearing age without contraceptive treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Arenal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel Arenal, MD, PhD</last_name>
    <phone>0034915868290</phone>
    <email>arenal@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gonzalo R. Ríos-Muñoz, MSc, PhD</last_name>
    <phone>0034915868290</phone>
    <email>gonzalo.rios.munoz@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ignacio Fernández Lozano, MD, PhD</last_name>
      <phone>0034911916000</phone>
      <email>iflozano@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Ignacio Fernández Lozano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Angel Arenal, MD, PhD</last_name>
      <phone>0034915868290</phone>
    </contact>
    <investigator>
      <last_name>Angel Arenal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gonzalo R. Ríos-Muñoz, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Soto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Arribas, MD, PhD</last_name>
      <phone>0034913908000</phone>
      <email>farribas@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Fernando Arribas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Radial ablation</keyword>
  <keyword>Rotors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

